| Budget Amount *help |
¥44,070,000 (Direct Cost: ¥33,900,000、Indirect Cost: ¥10,170,000)
Fiscal Year 2019: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
Fiscal Year 2018: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
Fiscal Year 2017: ¥10,140,000 (Direct Cost: ¥7,800,000、Indirect Cost: ¥2,340,000)
Fiscal Year 2016: ¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
|
|---|
| Outline of Final Research Achievements |
Boron neutron capture therapy (BNCT) is a radiation therapeutic method for cancer therapy. Current BNCT technology shows effective therapeutic benefits in refractory cancers such as brain tumor. However, improvement of insufficient cancer targeting and cellular uptake efficacy of boron compounds, and expansion of disease coverage in BNCT are strongly desired. In this research project, we aimed to develop BNCT technology using cell-penetrating peptides (CPPs) for enhanced cellular uptake of therapeutic boron compounds and their controlled locations inside cells, and antibody-based drug delivery technology for BNCT using Z33 peptide, which shows specific interaction recognition with the Fc of human IgG antibody, for on-demand receptor target. These results provide fundamental knowledge for the further development of receptor and organelle target system to control biological activity efficacy and to reduce side-effects of therapeutic boron compounds in BNCT.
|
